Valbenazine is a vesicular monoamine transporter 2 inhibitor used to treat tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesia has long been regarded as a consequence of anti-dopamine receptor therapy, and until 2008 with the advent of tetrabenazine, most treatments were ineffective.
- Mechanism
- Curator reviewed · 1 reference
Although the exact mechanism of action of valbenzine is still unknown, it is thought be mediated through the reversible inhibition of vesicular monoamine transporter 2 (VMAT2), a transporter that regulates monoamine uptake from the cytoplasm to the synaptic vesicle for storage and release.
- Primary indication
- Valbenazine is indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington’s disease.Curator reviewed · 2 structured indications
- Formula / weight
- C24H38N2O4 · 418.578 g/mol (avg)
- First approval
- United States, 2017
- Code names
- MT-5199 · NBI-98854
- Brand names
Resolves to
GEJDGVNQKABXKG-CFKGEZKQSA-NSMILESCOC1=C(OC)C=C2[C@H]3C[C@@H](OC(=O)[C@@H](N)C(C)C)[C@H](CC(C)C)CN3CCC2=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Valbenazine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account